Vicarious Surgical (RBOT) Stock Forecast, Price Target & Predictions
RBOT Stock Forecast
Vicarious Surgical stock forecast is as follows: an average price target of $6.00 (represents a 3.09% upside from RBOT’s last price of $5.82) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
RBOT Price Target
The average price target for Vicarious Surgical (RBOT) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $5.00. This represents a potential 3.09% upside from RBOT's last price of $5.82.
RBOT Analyst Ratings
According to 3 Wall Street analysts, Vicarious Surgical's rating consensus is 'Buy'. The analyst rating breakdown for RBOT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vicarious Surgical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 18, 2022 | - | BTIG | $7.00 | $3.50 | 100.00% | 20.27% |
| May 10, 2022 | - | Piper Sandler | $5.00 | $3.56 | 40.45% | -14.09% |
The latest Vicarious Surgical stock forecast, released on Jul 18, 2022 by BTIG company, set a price target of $7.00, which represents a 100.00% increase from the stock price at the time of the forecast ($3.50), and a 20.27% increase from RBOT last price ($5.82).
Vicarious Surgical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.82 | $5.82 | $5.82 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Vicarious Surgical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vicarious Surgical's last price of $5.82. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 18, 2022 | BTIG | Buy | Buy | Hold |
| May 10, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| Oct 19, 2021 | BTIG | - | Buy | Initialise |
Vicarious Surgical's last stock rating was published by Cowen & Co. on Aug 13, 2024. The company gave RBOT a "Buy" rating, the same as its previous rate.
Vicarious Surgical Financial Forecast
Vicarious Surgical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vicarious Surgical's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RBOT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vicarious Surgical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict RBOT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vicarious Surgical's previous annual EBITDA (undefined) of $NaN.
Vicarious Surgical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-15.55M | $-16.37M | $-16.51M | $-16.79M | $-14.87M | $-15.12M | $-15.97M |
| High Forecast | $-15.55M | $-16.37M | $-16.51M | $-16.79M | $-14.87M | $-14.31M | $-15.97M |
| Low Forecast | $-15.55M | $-16.37M | $-16.51M | $-16.79M | $-14.87M | $-15.87M | $-15.97M |
| Surprise % | - | - | - | - | - | - | - |
Vicarious Surgical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RBOT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vicarious Surgical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vicarious Surgical's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RBOT last annual SG&A of $NaN (undefined).
Vicarious Surgical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-2.65 | $-2.79 | $-2.81 | $-2.86 | $-2.53 | $-2.57 | $-2.72 |
| High Forecast | $-2.65 | $-2.79 | $-2.81 | $-2.86 | $-2.53 | $-2.44 | $-2.72 |
| Low Forecast | $-2.65 | $-2.79 | $-2.81 | $-2.86 | $-2.53 | $-2.70 | $-2.72 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vicarious Surgical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RBOT previous annual EPS of $NaN (undefined).
Vicarious Surgical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVRO | Nevro | $5.79 | $32.99 | 469.78% | Hold |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| MXCT | MaxCyte | $4.03 | $8.00 | 98.51% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| PROF | Profound Medical | $7.72 | $14.25 | 84.59% | Buy |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| CTKB | Cytek Biosciences | $4.91 | $8.50 | 73.12% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| RXST | RxSight | $54.96 | $68.60 | 24.82% | Buy |
| RBOT | Vicarious Surgical | $5.82 | $6.00 | 3.09% | Buy |
| BVS | Bioventus | $11.17 | $7.50 | -32.86% | Buy |
RBOT Forecast FAQ
Is Vicarious Surgical a good buy?
Yes, according to 3 Wall Street analysts, Vicarious Surgical (RBOT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of RBOT's total ratings.
What is RBOT's price target?
Vicarious Surgical (RBOT) average price target is $6 with a range of $5 to $7, implying a 3.09% from its last price of $5.82. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vicarious Surgical stock go up soon?
According to Wall Street analysts' prediction for RBOT stock, the company can go up by 3.09% (from the last price of $5.82 to the average price target of $6), up by 20.27% based on the highest stock price target, and down by -14.09% based on the lowest stock price target.
Can Vicarious Surgical stock reach $9?
RBOT's average twelve months analyst stock price target of $6 does not support the claim that Vicarious Surgical can reach $9 in the near future.
What are Vicarious Surgical's analysts' financial forecasts?
Vicarious Surgical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-45.963M (high $-45.152M, low $-46.716M), average SG&A $0 (high $0, low $0), and average EPS is $-7.826 (high $-7.688, low $-7.954). RBOT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-65.215M (high $-65.215M, low $-65.215M), average SG&A $0 (high $0, low $0), and average EPS is $-11.104 (high $-11.104, low $-11.104).